Published in Women's Health Weekly, October 5th, 2006
Researchers in Finland report, "Ospemifene is a novel selective estrogen receptor modulator (SERM) that is initially being developed for the treatment of vaginal atrophy in postmenopausal women. However, it also shows promise in the prevention and treatment of osteoporosis."
"As a part of a phase II trial, we compared the effects of ospemifene and raloxifene on bone turnover in postmenopausal women," wrote J. Komi and colleagues...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly